Long-term bomedemstat use in people with blood disorders who took it before
Follows people with essential thrombocythemia or polycythemia vera who continue bomedemstat.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Auckland, New ZealandSee the 2 sitesAlso in 5 other countries, 19 sites
- Trial code
- NCT06351631
- EU 2023-506996-89-00
- U1111-1294-8621
- Registry title
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 400 people, planned
- Started
- 23 May 2024
- Expected to end
- 4 Dec 2034
- Type of study
- Interventional
- Treatments tested
- Bomedemstat
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who took part in an earlier bomedemstat study, tolerate the drug well and benefit from it, according to the investigator.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- People with essential thrombocythemia, polycythemia vera or myelofibrosis who come from an earlier bomedemstat study.
- Earlier treatment
- Must have had bomedemstat in an earlier study. In study IMG-7289-202/MK-3543-005, at least 6 months of treatment. Essential thrombocythemia and polycythemia vera patients from other studies must have a confirmed hematologic response.
Main reasons for not taking part
- Has taken prohibited concomitant medications
- Is in, or plans to join, another investigational study
- Took less than 90% of the assigned doses in the earlier bomedemstat study
- Is currently on a dose hold
- Cannot swallow oral medication or follow at-home dosing instructions
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck \& Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic response, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
Who cannot take part
- Has received prohibited concomitant medications
- Has noncompliance in prior bomedemstat study receiving <90% of assigned doses excluding suspensions or holds as assigned by the investigator
- Ongoing or planned participation in another investigational study
Where in New Zealand
Also in 5 other countries, 19 sites
- Aotearoa Clinical Trials (Site 1400)Auckland, New ZealandContact: Toll Free NumberNo longer taking part
- North Shore Hospital-Department of Haematology (Site 1401)Auckland, New ZealandContact: Toll Free NumberNo longer taking part
About the trial
What the trial wants to find out
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria:
Read full original descriptionShow less
* Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response.
No hypothesis testing will be conducted in this study.
The group in the trial
- BomedemstatTreatment being tested
Participants will receive oral capsules of bomedemstat once daily for up to 10 years, with the starting dose as the same dose that the participant was on at the time of transition from the feeder study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
- Plain-language title
- Long-term bomedemstat use in people with blood disorders who took it beforeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 November 2026